---
title: "Otezla (apremilast) in plaque psoriasis: Safety questions"
description: "Safety questions on Otezla (apremilast) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Warnings, and Monitoring. Questions: What are the most common side effects of Otezla for plaque psoriasis? What side effects did Otezla cause in mild to moderate plaque psoriasis (ADVANCE)? What are the side effects of Otezla in children with plaque psoriasis? What side effects did Otezla cause in scalp psoriasis (STYLE)? 5 further questions follow. 9 questions quoted from 8 sources."
canonical: "https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Otezla (apremilast) in plaque psoriasis: Safety questions

Manufacturer: Amgen Inc.  
Prescribing information: [Otezla](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf)

Safety questions that apply to every indication of Otezla are on [Otezla (apremilast), all indications: Safety](https://www.evicenter.com/medical-information/otezla/safety).

## Side effects

<a id="otezla-side-effects"></a>

### What are the most common side effects of Otezla for plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)

> “Plaque Psoriasis: The most common adverse reactions (≥ 5%) are diarrhea, 
> nausea, upper respiratory tract infection, and headache, including tension 
> headache (6.1)”

Source: [OTEZLA: Prescribing information, page 1, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=1)

> “Diarrhea, nausea, and upper respiratory tract infection were the most commonly reported adverse 
> reactions (see Table 4). The most common adverse reactions leading to discontinuation for subjects taking 
> OTEZLA were nausea (1.6%), diarrhea (1.0%), and headache (0.8%). The proportion of subjects with 
> plaque psoriasis who discontinued treatment due to any adverse reaction was 6.1% for subjects treated 
> with OTEZLA 30 mg twice daily and 4.1% for placebo-treated subjects.”

Source: [OTEZLA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=10)

> “Table 4. Adverse Reactions Reported in ≥ 1% of Adult Subjects with Moderate to Severe Plaque 
> Psoriasis on OTEZLA and With Greater Frequency Than in Subjects on Placebo up to Day 112 
> (Week 16) 
>
> Adverse Reactions 
> Placebo (N = 506) 
> n (%) 
> OTEZLA 30 mg BID<sup>b</sup> (N = 920) 
> n (%) 
> Diarrhea 
> 32 (6) 
> 160 (17) 
> Nausea 
> 35 (7) 
> 155 (17) 
> Upper respiratory tract 
> infection 
> 31 (6) 
> 84 (9) 
> Tension headache 
> 21 (4) 
> 75 (8) 
> Headache 
> 19 (4) 
> 55 (6) 
> Abdominal pain<sup>a</sup> 
> 11 (2) 
> 39 (4) 
> Vomiting 
> 8 (2) 
> 35 (4) 
> Fatigue 
> 9 (2) 
> 29 (3) 
> Dyspepsia 
> 6 (1) 
> 29 (3) 
> Decreased appetite 
> 5 (1) 
> 26 (3) 
> Insomnia  
> 4 (1) 
> 21 (2) 
> Back pain 
> 4 (1) 
> 20 (2) 
> Migraine 
> 5 (1) 
> 19 (2) 
> Frequent bowel movements 
> 1 (0) 
> 17 (2) 
> Depression 
> 2 (0) 
> 12 (1) 
> Bronchitis 
> 2 (0) 
> 12 (1) 
> Tooth abscess 
> 0 (0) 
> 10 (1) 
> Folliculitis 
> 0 (0) 
> 9 (1) 
> Sinus headache 
> 0 (0) 
> 9 (1) 
> <sup>a</sup> Two subjects treated with OTEZLA experienced serious adverse reaction of abdominal pain. 
> <sup>b</sup>   BID = twice daily.”

Source: [OTEZLA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=10)

Note: Table 4 columns are placebo (N = 506) and OTEZLA 30 mg twice daily (N = 920), each as number (%) of subjects through Week 16.

<a id="otezla-side-effects-mild-moderate"></a>

### What side effects did Otezla cause in mild to moderate plaque psoriasis (ADVANCE)?

Applies to: Mild to moderate plaque psoriasis in adults with an inadequate response or intolerance to topical therapy (ADVANCE; PSOR-4 in the label)

> “The most commonly reported TEAEs that occurred in ≥5% of patients in either treatment group were diarrhea, headache, nausea, nasopharyngitis, and upper respiratory tract infection <sup>1</sup>”

Source: [OTEZLA: Established Safety: Mild to Moderate Plaque PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/mild-to-moderate/#:~:text=The%20most%20commonly%20reported%20TEAEs,and%20upper%20respiratory%20tract%20infection)

> “OTEZLA was evaluated in a Phase 3, multicenter, randomized, placebo-controlled trial (PSOR-4) in adult 
> subjects with mild to moderate plaque psoriasis [see Clinical Studies (14.4)]. A total of 595 subjects were 
> randomized to receive OTEZLA 30 mg twice daily (297 subjects) or placebo twice daily (298 subjects) 
> during the placebo-controlled phase of the trial. The trial also included an open label extension phase 
> during which all subjects received OTEZLA 30 mg twice daily. Overall, the safety profile observed in the 
> OTEZLA group during the placebo-controlled phase was consistent with the safety profile previously 
> established in adult subjects with moderate to severe plaque psoriasis.”

Source: [OTEZLA: Prescribing information, page 11, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=11)

Note: The ADVANCE adverse event rates are shown in an image on the safety page and are not quoted.

<a id="otezla-side-effects-children"></a>

### What are the side effects of Otezla in children with plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy and weigh at least 20 kg (OTEZLA) or at least 50 kg (OTEZLA XR)

> “OTEZLA was evaluated in a Phase 3, multicenter, randomized, placebo-controlled trial (PSOR-6) in 
> pediatric subjects 6 to 17 years of age with moderate to severe plaque psoriasis [see Clinical Studies 
> (14.3)]. A total of 245 subjects were randomized to receive OTEZLA (163 subjects, at a dosage of 20 mg 
> twice daily or 30 mg twice daily, based on body weight) or placebo (82 subjects) twice daily during the 
> 16-week placebo-controlled phase of the trial. The trial also included a 36-week extension phase during 
> which all subjects received OTEZLA 20 mg or 30 mg twice daily. Overall, the safety profile observed in 
> pediatric subjects treated with OTEZLA during the study was consistent with the safety profile 
> established in adult subjects with moderate to severe plaque psoriasis.”

Source: [OTEZLA: Prescribing information, page 11, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=11)

> “Most events were mild to moderate, with the most common adverse events being diarrhea, nausea,
> abdominal pain, and vomiting <sup>1</sup>”

Source: [OTEZLA: SPROUT: Weeks 0 to 16 Safety, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/sprout/#:~:text=Most%20events%20were%20mild%20to,abdominal%20pain%2C%20and%20vomiting)

> “Reasons for discontinuation primarily included withdrawal by the patient or parent/guardian (13/245 [5.3%]) and adverse events (6/245 [2.4%])”

Source: [OTEZLA: SPROUT: Weeks 0 to 16 Safety, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/sprout/#:~:text=Reasons%20for%20discontinuation%20primarily%20included,and%20adverse%20events%20%286%2F245%20%5B2.4%25%5D%29)

Note: The SPROUT adverse event rates are shown in an image on the pediatric safety page and are not quoted.

<a id="otezla-scalp-side-effects"></a>

### What side effects did Otezla cause in scalp psoriasis (STYLE)?

Applies to: Moderate to severe plaque psoriasis of the scalp in adults (STYLE; PSOR-3 in the label)

> “OTEZLA was evaluated in a Phase 3, multicenter, randomized, placebo-controlled trial (PSOR-3) in 
> adults with moderate to severe plaque psoriasis of the scalp [see Clinical Studies (14.2)]. A total of 
> 302 subjects were randomized to receive OTEZLA 30 mg twice daily or placebo twice daily. The most 
> commonly reported adverse reactions that occurred at a higher rate in the OTEZLA group than in the 
> placebo group were: diarrhea (31% vs. 11%), nausea (22% vs. 6%), headache (12% vs. 5%), and 
> vomiting (6% vs. 2%). The proportion of subjects who discontinued treatment because of any adverse 
> reaction during the 16-week placebo-controlled period of the trial was 6% for subjects who received 
> OTEZLA 30 mg twice daily and 3% for subjects who received placebo. Gastrointestinal adverse reactions 
> that led to discontinuation of treatment were diarrhea (3% vs. 0%), nausea (1.5% vs. 1%), and vomiting 
> (1.5% vs. 0%) in the OTEZLA group compared to placebo.”

Source: [OTEZLA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=10)

Note: The Prescribing Information names the trial PSOR-3; the Otezla HCP site names it STYLE.

<a id="otezla-long-term-side-effects"></a>

### What are the long-term side effects of Otezla through 5 years (ESTEEM)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)

> “IN ESTEEM, THE LONG-TERM SAFETY PROFILE OF OTEZLA WAS CONSISTENT THROUGH 5 YEARS OF EXPOSURE”

Source: [OTEZLA: Established Safety: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/moderate-to-severe/#:~:text=IN%20ESTEEM%2C%20THE%20LONG%2DTERM%20SAFETY,THROUGH%205%20YEARS%20OF%20EXPOSURE)

> “<sup>‡‡</sup>Includes all patients in the ESTEEM trials who received Otezla during the time interval relative to the start of Otezla administration.”

Source: [OTEZLA: Established Safety: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/moderate-to-severe/#:~:text=all%20patients%20in%20the%20ESTEEM,the%20start%20of%20Otezla%20administration.)

> “Discontinuation due to adverse reactions occurred at 7.6% during weeks 0 to ≤52, 3.7% during weeks >52 to ≤104, 3.5% during weeks >104 to ≤156, 3.8% during weeks >156 to ≤208, and 1.9% during weeks >208 to ≤260 <sup>7</sup>”

Source: [OTEZLA: Established Safety: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/moderate-to-severe/#:~:text=Discontinuation%20due%20to%20adverse%20reactions,during%20weeks%20%3E208%20to%20%E2%89%A4260)

> “Consider open-label extension (OLE) study limitations when interpreting results. The OLE is not blinded, not controlled, and includes self-selection bias. Of the 443 patients treated with apremilast from weeks 52 to 260, 26.6% (n=118) discontinued due to lack of efficacy, 22.6% (n=100) withdrew from the study, 8.6% (n=38) discontinued due to an adverse event, and 7.0% (n=31) were lost to follow-up <sup>3</sup>”

Source: [OTEZLA: PASI-75 Response in PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/pasi-75/#:~:text=Consider%20open%2Dlabel%20extension%20%28OLE%29%20study,%28n%3D31%29%20were%20lost%20to%20follow%2Dup)

Note: The adverse reaction rates through week 260 are shown in an image on the safety page and are not quoted. The open-label extension caveat accompanies the ESTEEM 1 PASI-75 results through week 260 on the PASI-75 efficacy page; it states that the extension (weeks 52 to 260) was not blinded or controlled.

## Safety

<a id="otezla-mace-serious-infections"></a>

### Did Otezla increase serious infections or MACE vs placebo at 16 weeks (ESTEEM)?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)

> “<sup>†††</sup>Increased exposure to Otezla did not contribute to an increase in incidence rates of MACE or serious infections compared to placebo at week 16.”

Source: [OTEZLA: Established Safety: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/moderate-to-severe/#:~:text=exposure%20to%20Otezla%20did%20not,to%20placebo%20at%20week%2016.)

> “ESTEEM 1 & 2: Adverse events of special interest through week 16 and through 5 years <sup>8,§§</sup>”

Source: [OTEZLA: Established Safety: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/moderate-to-severe/#:~:text=ESTEEM%201%20%26%202%3A%20Adverse%20events,16%20and%20through%205%20years)

> “<sup>§§</sup>EAIR/100 PY is the exposure-adjusted incident rate per 100 patient years. ***In the Otezla 30 mg BID group, events included acute myocardial infarction (AMI).<sup>8</sup>”

Source: [OTEZLA: Established Safety: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/safety/moderate-to-severe/#:~:text=PY%20is%20the%20exposure%2Dadjusted%20incident,events%20included%20acute%20myocardial%20infarction)

Note: The comparison with placebo covers the 16-week placebo-controlled period of ESTEEM 1 and ESTEEM 2; the incidence rates through week 16 and through 5 years are shown in an image on the safety page and are not quoted. MACE is major adverse cardiovascular events.

## Warnings

<a id="otezla-weight-loss"></a>

### Does Otezla cause weight loss?

> “Weight loss may occur in adult or pediatric patients treated with OTEZLA/OTEZLA XR. 
>
> Regularly monitor the weight of patients treated with OTEZLA/OTEZLA XR. If unexplained or clinically 
> significant weight loss occurs, evaluate weight loss and consider discontinuation of OTEZLA/OTEZLA 
> XR [see Adverse Reactions (6.1)].”

Source: [OTEZLA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=7)

> “During the placebo-controlled period of the trials in adults with moderate to severe plaque psoriasis, 
> weight decrease between 5%-10% of body weight occurred in 12% (96/784) of subjects treated with 
> OTEZLA compared to 5% (19/382) treated with placebo. Weight decrease of ≥ 10% of body weight 
> occurred in 2% (16/784) of subjects treated with OTEZLA 30 mg twice daily compared to 1% (3/382) 
> subjects treated with placebo.”

Source: [OTEZLA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=7)

> “During the placebo-controlled period of the clinical trial in adults with mild to moderate plaque psoriasis, 
> weight decrease was similar to what was observed in the trials of adults with moderate to severe plaque 
> psoriasis.”

Source: [OTEZLA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=7)

> “During the placebo-controlled period of the clinical trial in pediatric subjects 6 years of age and older 
> with moderate to severe plaque psoriasis, weight decrease between 5%-10% of body weight occurred in 
> 12% (19/163) of pediatric subjects treated with OTEZLA compared to 2.5% (2/80) of pediatric subjects 
> treated with placebo.”

Source: [OTEZLA: Prescribing information, page 8, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=8)

## Monitoring

<a id="otezla-lab-monitoring"></a>

### Does Otezla require lab monitoring?

> “No initial or ongoing
> lab monitoring <sup>1</sup>”

Source: [OTEZLA: Plaque Psoriasis (PsO) Treatment, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/#:~:text=No%20initial%20or%20ongoing,lab%20monitoring)

> “Regularly monitor the weight of patients treated with OTEZLA/OTEZLA XR. If unexplained or clinically 
> significant weight loss occurs, evaluate weight loss and consider discontinuation of OTEZLA/OTEZLA 
> XR [see Adverse Reactions (6.1)].”

Source: [OTEZLA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=7)

Note: The Prescribing Information recommends regular weight monitoring, and close monitoring of growth in pediatric patients.

<a id="otezla-tb-testing"></a>

### Does Otezla require TB testing before treatment starts?

> “No lab monitoring. No TB or baseline blood panel tests. No planning around live vaccines <sup>1</sup>”

Source: [OTEZLA: Otezla® (apremilast) Healthcare Professional (HCP) Website, captured 2026-11-13](https://www.otezlapro.com/#:~:text=No%20lab%20monitoring.%20No%20TB,No%20planning%20around%20live%20vaccines)

> “Active TB or incompletely treated TB; however, there was no requirement for latent TB screening”

Source: [OTEZLA: ESTEEM Study Design for PsO l, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/study-design/esteem/#:~:text=Active%20TB%20or%20incompletely%20treated,requirement%20for%20latent%20TB%20screening)

Note: The second passage is a selected exclusion criterion of the ESTEEM trials, from the ESTEEM study design page.

## Related pages
- [Medical information: Otezla (apremilast): Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/dosing-and-administration)
